RxDoctor Payments Data

Rafael Ortiz, MD

Ophthalmology · Miami, FLNPI 1225186067

Payments from drug & device makers

$108,891in general payments, 2019–2025

Across 87 payments — averaging $1251.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$106K
  • AbbVie$2K
  • Aerie Pharmaceuticals, Inc.$219
  • Astellas Pharma US Inc$149
  • Novartis$101
  • Apellis Pharmaceuticals, Inc.$101
  • plus $314 from 9 others

What the payments were for

  • Food & beverage$1,395100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$108,891 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$461,787
Medicare patients
344
Services billed
5,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine62$63,396
RhopressaNetarsudil Mesylate93$45,060
VyzultaLatanoprostene Bunod115$40,745
LumiganBimatoprost39$26,788
XiidraLifitegrast16$13,804
Cyclosporine30$10,430
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$5,576
Azelastine Hcl159$5,129
SimbrinzaBrinzolamide/Brimonidine Tart22$5,006
Brimonidine Tartrate95$3,589
Ketorolac Tromethamine81$2,152
Latanoprost197$1,926
Dorzolamide Hcl92$1,737
Timolol Maleate53$725
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$2,212$90,183101 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$24$54,548131 claims
Aerie Pharmaceuticals, Inc.Rhopressa$219$45,06093 claims
AlconSimbrinza$46$5,00622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →